413 completed, 20 withdrawn, 18 terminated, 15 unknown. 492 Phase 2, 108 Phase 1, 40 Phase 3.
Follow Influenza, Human: new trials by email Literature Review of Influenza, Human trials Research Report on Influenza, Human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BPL-1357 Against H1N1 Influenza Virus Challenge BPL-1357 IM, BPL-1357 IN, Placebo IM - Influenza, Human | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 129 | 2026-11-04 | 2026-10-30 |
| Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza 20 mg 102D-6 dry suspension, 40 mg 102D-6 dry suspension, Placebo - Influenza, Human | Phase 2 / Phase 3 | Not yet recruiting | Capital Medical University | 570 | 2026-10-21 | 2026-10-26 |
| A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza. SYH2085, Placebo - Influenza | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 213 | 2026-10-10 | 2026-09-01 |
| Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older vaccination of GC3114B, Vaccination of Efluelda - Influenza A, Influenza B, Influenza Vaccination | Phase 2 / Phase 3 | Not yet recruiting | GC Biopharma Corp | 1806 | 2026-10-01 | 2026-10-20 |
| Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant - Healthy Volunteers, Influenza | Phase 1 / Phase 2 | Recruiting | Sanofi | 640 | 2026-08-03 | 2026-09-15 |
| Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model TRX-100, Placebo, Influenza A/France/759/2021 (H1N1) virus - Influenza | Phase 2 | Not yet recruiting | Traws Pharma, Inc. | 165 | 2026-06-01 | 2026-03-31 |
| Study to Investigate the Efficacy and Safety of Apomivir® Apomivir®, Placebo - Influenza | Phase 2 | Not yet recruiting | Far East Bio-Tec Co., Ltd | 196 | 2026-05-31 | 2025-05-14 |
| Vaccination Response Modulation With a Targeted Rapamycin Protocol Study Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), RSV vaccine (Pfizer Abrysvo) - Vaccine Immune Response, Haemodialysis Patients | Phase 2 | Not yet recruiting | Central Adelaide Local Health Network Incorporated | 60 | 2026-05-01 | 2026-05-14 |
| A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses AP1189, 100 mg, Placebo - Respiratory Viral Infection | Phase 2 | Recruiting | SynAct Pharma Aps | 96 | 2026-05-01 | 2026-07-28 |
| Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine Recombinant Influenza vaccine candidate, Commercial Influenza vaccine - Influenza | Phase 1 / Phase 2 | Active not recruiting | Aramis Biotechnologies Inc. | 728 | 2026-02-25 | 2026-08-04 |
| A Study to Learn About mRNA Vaccines Against Influenza in Adults Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3 - Healthy Adults | Phase 2 | Recruiting | Pfizer | 770 | 2026-02-23 | 2026-05-06 |
| Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine - Influenza | Phase 2 | Not yet recruiting | Shanghai Institute Of Biological Products | 1200 | 2026-01-07 | 2026-01-15 |
| This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza TRX-100, Standard of Care (SOC) - Influenza | Phase 2 | Active not recruiting | Traws Pharma, Inc. | 105 | 2025-12-15 | 2026-03-27 |
| A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) MK-1406 Injection - Healthy Participants | Phase 2 | Active not recruiting | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 400 | 2025-10-29 | 2026-08-20 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections. Ingavirin Forte, 90 mg + 5 mg, Capsules, Ingavirin Forte, 90 mg + 10 mg, Capsules, Ingavirin Forte, 90 mg + 20 mg, Capsules - Influenza, Acute Respiratory Viral Infection | Phase 2 | Recruiting | Valenta Pharm JSC | 300 | 2025-10-24 | 2026-02-19 |
| A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A) - Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 971 | 2025-10-07 | 2026-09-18 |
| High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine - Immunization; Infection|Transplantation Infection|Influenza, Influenza | Phase 2 | Recruiting | Vanderbilt University Medical Center | 60 | 2025-09-17 | 2026-10-21 |
| Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg OVX836 480µg, Saline Solution - Influenza | Phase 2 | Completed | Osivax | 2891 | 2025-09-08 | 2026-10-16 |
| Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection SNG001, Placebo - Viral Pneumonia | Phase 2 | Terminated | Synairgen Research Ltd. | 11 | 2025-09-02 | 2026-09-14 |
| A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1 - Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 776 | 2025-08-25 | 2026-05-28 |
Showing 20 of 492. Sign in to see all of them.
Orthomyxoviridae Infections (34) · Influenza in Birds (32) · Virus Diseases (23) · Respiratory Tract Infections (18) · COVID-19 (15) · Infections (15) · Respiratory Tract Diseases (12) · RNA Virus Infections (8) · Communicable Diseases (5) · Common Cold (3) · Coronary Artery Disease (3) · Coronavirus Infections (3) · Neoplasms (3) · Angina, Stable (2)
RNA Virus Infections (484) · Respiratory Tract Diseases (480) · Infections (477) · Respiratory Tract Infections (474) · Virus Diseases (469) · Orthomyxoviridae Infections (458) · Animal Diseases (32) · Bird Diseases (32) · Coronaviridae Infections (17) · Nidovirales Infections (17) · Pathological Conditions, Signs and Symptoms (17) · Immune System Diseases (15) · Lung Diseases (15) · Pneumonia, Viral (15) · Coronavirus Infections (14)
Influenza Vaccines (98) · Oseltamivir (22) · fluarix (21) · Sodium Chloride (13) · Vaccines (12) · vaxigrip (11) · FluMist (8) · MF59 oil emulsion (7) · Antigens, Surface (6) · Fluzone High-Dose (6) · Saline Solution (6) · mRNA-1010 influenza vaccine (6) · peramivir (5) · Adjuvants, Pharmaceutic (4) · Aluminum Hydroxide (4)
National Institute of Allergy and Infectious Diseases (NIAID) (65) · GlaxoSmithKline (56) · Sanofi Pasteur, a Sanofi Company (38) · Novartis Vaccines (28) · Seqirus (14) · Novartis (13) · MedImmune LLC (12) · Alachua Government Services, Inc. (11) · ModernaTX, Inc. (10) · Novavax (10) · Sanofi (8) · Medicago (7) · BiondVax Pharmaceuticals ltd. (6) · Osivax (6) · University of Oxford (6)
United States (228) · United Kingdom (37) · Belgium (32) · Canada (32) · Australia (28) · Germany (18) · Italy (18) · France (17) · Russia (17) · China (15) · Thailand (14) · Spain (12) · Finland (11) · South Africa (11) · Austria (10)
Robert Walker, MD (5) · John Treanor, MD (4) · Michael Libman, MD (4) · Eric Sheldon, MD (3)
PMID 39756216, PMID 20018365, PMID 22537984, PMID 25222307, PMID 30953061, PMID 30968056, PMID 31166987, PMID 37739792, PMID 15545863, PMID 16571878, PMID 17029131, PMID 17426277, PMID 18187561, PMID 18237269, PMID 18260764, PMID 18550874, PMID 18599164, PMID 18652550, PMID 18676527, PMID 18801398, PMID 18808338, PMID 19064822, PMID 19112513, PMID 19197383, PMID 19237568, PMID 19261173, PMID 19341446, PMID 19416838, PMID 19561422, PMID 19569973, PMID 19577636, PMID 19673652, PMID 19712040, PMID 19716456, PMID 19761837, PMID 19840662, PMID 19846844, PMID 20018364, PMID 20375709, PMID 20377407, PMID 20581690, PMID 20600478, PMID 20620116, PMID 20819892, PMID 20874515, PMID 20980795, PMID 21108818, PMID 21219979, PMID 21282194, PMID 21288852
2009 (9), 2016 (5), 2008 (4), 2015 (4), 2025 (3), 2023 (2), N01AI30025 (2), 2014 (1), 2017 (1), 2018 (1), K23GM101463 (1), N01AI30039 (1), R01AT004313 (1), R01AT006970 (1), U19AI089992 (1)